PUTNAM MUN OPPORTUNITIES TR (PMO)

Overview Price 12.62 Price Change Today -$0.05 (-0.39%) P&P rating Zacks Rank N/A - N/A Open Price $12.67 Previous Close $12.67 Daily Range $12.58 - $12.67 52-Week Range $10.46 - $12.75 Volume 108,524 Putnam Municipal Opportunities Trust is a non-diversified, closed-end management investment company. Other Resources for PMO Detailed Quote Earnings Estimates Company Report Interactive Chart Commentary No Commentary Found for This Ticker. Putnam Municipal Opportunities Trust is a non-diversified, closed-end management investment company.   No brokerage coverage for PMO   PMO Ratings: BUY  SELL  HOLD PMO Consensus Forecasts

Rate this Stock! You haven't rated this stock yet! Ticker Call Buy Sell Analysis Time Frame Week or Less Week to a Month One to Three Months Three to Six Months Six Months to a Year One to Three Years Three Plus Years What The Community Thinks Total Players 0 Buy 0 Sell   Top Buy Analysis No Buy Analysis. Be the First. More Recent Analysis Top Sell Analysis No Sell Analysis. Be the First. More Recent Analysis

Blog Posts

User	User Score	Date	Title	Comments	Last Comment
Zacks_Analysts	0.00	05/25/11	AstraZeneca Inks Daiichi Deal - Analyst Blog	0
Zacks_Analysts	0.00	08/25/10	Encouraging Results from AVII - Analyst Blog	0
Zacks_Analysts	0.00	07/20/10	Zacks Analyst Blog Highlights: Jinpan International, Whole Foods Market, Amgen, Novartis and GlaxoSmithKline - Press Releases	0
Zacks_Analysts	0.00	07/19/10	Priority Review for Amgen Drug - Analyst Blog	0
Zacks_Analysts	0.00	06/03/10	Zacks Analyst Blog Highlights: Amgen, Novartis, GlaxoSmithKline, Merck and Eli Lilly - Press Releases	0
Zacks_Analysts	0.00	06/02/10	Amgen's Prolia Approved in U.S. - Analyst Blog	0
Zacks_Analysts	0.00	05/24/10	Zacks Analyst Blog Highlights: Amgen, Novartis, Merck, GlaxoSmithKline and Eli Lilly - Press Releases	0
Zacks_Analysts	0.00	05/21/10	Amgen Submits for Denosumab - Analyst Blog	0
Zacks_Analysts	0.00	04/22/10	Amgen Beats but Tones Down Outlook - Analyst Blog	0
Zacks_Analysts	0.00	02/22/10	Amgen's Date with the FDA - Analyst Blog	0

Pages: [ 1 ]  2  >>

Commentary

There are no open picks with this stock at the moment.

Picks

There are no open picks with this stock at the moment.